BAYRY - Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details | Benzinga
Bayer AG (OTC: BAYRY) (OTC: BAYZF) stopped the OCEANIC-AF Phase 3 study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial fibrillation at risk for stroke.
The decision is based on the study's Independent Data Monitoring Committee (IDMC) recommendation as part of ongoing surveillance, which showed an inferior efficacy of asundexian versus the control arm.
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc’s (NYSE: PFE) apixaban ...